|
|
 |
|
Viewing report
|
|
|
|
Stakeholder Opinions: Non-Hodgkins Lymphoma - Is there room to emulate Rituxans success?
Datamonitor, Dec 2007, Pages: 174
Non-Hodgkins lymphoma (NHL) is the most common hematological malignancy and is comprised of around 30 different disease subtypes. Each of these present with a distinct set histological, genetic and clinical characteristics.
Treatment options in NHL include chemotherapy, targeted therapies, stem cell transplantation and radiotherapy.
Scope
- NHL background and epidemiology, including forecast incidence of the major subtypes in the seven major markets
- Treatment of NHL by subtype and line of therapy, including major treatment controversies and areas of unmet need
- Examination of pipeline activity including profiles of late-phase pipeline drugs
- Stakeholder opinions based on qualitative interviews with opinion leaders from the US and Europe
Highlights of this title
Rituxan-based regimens constitute the mainstay of first-line treatment options in several NHL subtypes. Uptake of Rituxan in the maintenance setting for follicular lymphoma (FL) has allowed the drug to achieve further market penetration.
There is a lack of consensus over the treatment of relapsed and refractory disease in most NHL subtypes. Refractory patients are poorly served by currently available treatment options. Other unmet needs include detection of patients with aggressive lymphoma at high risk of relapse and an efficacious maintenance therapy for these patients.
The NHL late-phase pipeline is relatively active, with 10 Phase IIII drugs and 46 Phase II drugs. Monoclonal antibodies are among those agents that continue to demonstrate promising signs of clinical and commercial potential. However, Rituxans status as market leader is unlikely to be challenged within the next 510 years.
Key reasons to purchase this title
- Understand current epidemiological trends in non-Hodgkins lymphoma and ongoing treatment options
- Identify limitations of therapy currently available to non-Hodgkins lymphoma patients and the potential of future therapy
- Identify the key products in late-phase development for NHL. Consider, assess and react to opportunities and risks influencing their future potential
Customers who bought this item also bought
Stakeholder Opinions: Non-Hodgkins Lymphoma - Is there room to emulate Rituxans success?
Success Stories: Japan
The Roadmap to Offshore Success: Strategy and Best Practices for Enterprise Software Companies
Preclinical Cancer Therapeutics 2007: Decoding Next Generation Drug Targets for Market Success
Driving Corporate Culture For Business Success
Product Relaunch Excellence: Transforming Lackluster Pharmaceutical Products into Market Success Stories
The Essential Online Solution: The 5-Step Formula for Small Business Success
The Emotionally Intelligent Team: Understanding and Developing the Behaviors of Success
|
|
|
|
